Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C76H52O46.C20H31NO3 |
| Molecular Weight | 2034.6635 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCOCCOC(=O)C1(CCCC1)C2=CC=CC=C2.OC3=CC(=CC(O)=C3O)C(=O)OC4=CC(=CC(O)=C4O)C(=O)OC[C@H]5O[C@@H](OC(=O)C6=CC(O)=C(O)C(OC(=O)C7=CC(O)=C(O)C(O)=C7)=C6)[C@H](OC(=O)C8=CC(O)=C(O)C(OC(=O)C9=CC(O)=C(O)C(O)=C9)=C8)[C@@H](OC(=O)C%10=CC(O)=C(O)C(OC(=O)C%11=CC(O)=C(O)C(O)=C%11)=C%10)[C@@H]5OC(=O)C%12=CC(O)=C(O)C(OC(=O)C%13=CC(O)=C(O)C(O)=C%13)=C%12
InChI
InChIKey=LILZIIRVLKMYCP-HBNMXAOGSA-N
InChI=1S/C76H52O46.C20H31NO3/c77-32-1-22(2-33(78)53(32)92)67(103)113-47-16-27(11-42(87)58(47)97)66(102)112-21-52-63(119-72(108)28-12-43(88)59(98)48(17-28)114-68(104)23-3-34(79)54(93)35(80)4-23)64(120-73(109)29-13-44(89)60(99)49(18-29)115-69(105)24-5-36(81)55(94)37(82)6-24)65(121-74(110)30-14-45(90)61(100)50(19-30)116-70(106)25-7-38(83)56(95)39(84)8-25)76(118-52)122-75(111)31-15-46(91)62(101)51(20-31)117-71(107)26-9-40(85)57(96)41(86)10-26;1-3-21(4-2)14-15-23-16-17-24-19(22)20(12-8-9-13-20)18-10-6-5-7-11-18/h1-20,52,63-65,76-101H,21H2;5-7,10-11H,3-4,8-9,12-17H2,1-2H3/t52-,63-,64+,65-,76+;/m1./s1
DescriptionSources: http://www.rxwiki.com/pentoxyverineCurator's Comment: Description was created using several sources including:
http://www.ncbi.nlm.nih.gov/pubmed/3768695 |
http://www.ncbi.nlm.nih.gov/pubmed/8057277 |
https://www.drugs.com/cdi/solotuss-suspension.html | http://www.drugsupdate.com/generic/view/1197/Pentoxyverine
Sources: http://www.rxwiki.com/pentoxyverine
Curator's Comment: Description was created using several sources including:
http://www.ncbi.nlm.nih.gov/pubmed/3768695 |
http://www.ncbi.nlm.nih.gov/pubmed/8057277 |
https://www.drugs.com/cdi/solotuss-suspension.html | http://www.drugsupdate.com/generic/view/1197/Pentoxyverine
Pentoxyverine is a non-opioid antitussive used to prevent cough caused by common cold. It is used as an active ingredient of several oral over-the-counter cough suppressants alone or in combination with other medications, especially decongestants. Certuss is a combination of pentoxyverine and guaifenesin. Pentoxyverine is FDA pregnancy category C drug. Known as anticonvulsant, and spasmolytic agent.
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
30 mg 3 times / day multiple, oral (mother), breasteeding (infant) Overdose Dose: 30 mg, 3 times / day Route: oral (mother), breasteeding (infant) Route: multiple Dose: 30 mg, 3 times / day Sources: |
healthy, infant n = 1 Health Status: healthy Age Group: infant Population Size: 1 Sources: |
Disc. AE: Respiratory failure... AEs leading to discontinuation/dose reduction: Respiratory failure (acute, 1 patient) Sources: |
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: productive cough Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Respiratory failure | acute, 1 patient Disc. AE |
30 mg 3 times / day multiple, oral (mother), breasteeding (infant) Overdose Dose: 30 mg, 3 times / day Route: oral (mother), breasteeding (infant) Route: multiple Dose: 30 mg, 3 times / day Sources: |
healthy, infant n = 1 Health Status: healthy Age Group: infant Population Size: 1 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Capacitive sensors using electropolymerized o-phenylenediamine film doped with ion-pair complex as selective elements for the determination of pentoxyverine. | 2004 Jun 17 |
|
| Study on the enhancement of Ru(bpy)3(2+) electrochemiluminescence by nanogold and its application for pentoxyverine detection. | 2005 Dec |
|
| Effects of common antitussive drugs on the hERG potassium channel current. | 2008 Dec |
|
| [Quantification of pentoxyverine citrate in human plasma by LC-ESI/MS method and its application]. | 2009 Dec |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB14802MIG
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY | |||
|
23K1F351T7
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY | |||
|
C018861
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY | |||
|
1406-98-0
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY | |||
|
155491346
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY | PUBCHEM | ||
|
DBSALT002765
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY | |||
|
221070
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY | RxNorm | ||
|
Carbetapentane tannate
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY | |||
|
100000088537
Created by
admin on Fri Dec 15 17:48:26 GMT 2023 , Edited by admin on Fri Dec 15 17:48:26 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
